Posts Tagged ‘Dow corning breast implant lawyer’
The Claimants’ Advisory Committee (CAC) is the official committee appointed by the U.S. District Court in the Eastern District of Michigian to represent the interests of women in the Dow Corning Bankruptcy Settlement Plan. They have a website with information concerning the Settlement Facility for the Dow Corning Trust (SF-DCT).
Phone Number: 419-394-0717
Email address: firstname.lastname@example.org,
Mailing address: Claimants’ Advisory Committee, P.O. Box 665, St. Marys, OH 45885.
You can also sign up on the website to receive a free copy of their monthly electronic newsletter by e-mail.
LATEST COURT ORDERS ON THE WEBSITE
July 31, 2014 – 6th Circuit Court of Appeals affirmed that tissue expanders are included in the definition of “Breast Implants” June 20, 2014 – Stipulation and Order Recommending the Appointment of the Honorable Pamela R. Harwood as Lien Judge March 31, 2014 – 6th Circuit Court of Appeals ruled Denying Dow Corning’s Motion to Stay Partial Premium Payments February 25, 2014 – Order Denying Motion to Stay Pending Appeal.
LINKS TO RELATED WEBSITES
Settlement Facility website: www.dcsettlement.com
Email address: email@example.com
Mailing address: Settlement Facility – DC Trust P.O. Box 52429 Houston, TX 77052-2429
Phone Number: (713) 874-6099
Toll free Phone Number: (866) 874-6099 (within the U.S.)
International Toll Free Number AT&T Direct Access Number: + 866 + 874 6099 (outside the U.S.)
MDL 926 Claims Office for the Revised Settlement Program:
Website: www.fjc.gov (MDL 926 Court)
Website: www.claimsoffice-926.com (MDL 926 Claims Office) The MDL 926 Claims Office website is still under development, so some “headings” do not have any information listed. Additional information will be posted as it becomes available.
Email address: firstname.lastname@example.org
Mailing address: MDL 926 Claims Office P.O. Box 56666 Houston, TX 77256
Phone Number: 1-800-600-0311
United States District Court for the Eastern District of Michigan
Website address: www.mied.uscourts.gov
For a Dow Corning Breast Implant Lawyer contact the Dow Corning Breast Implant Helpline
Our lawyers are private practice lawyers. They are not employed by or affiliated with the Dow Corning Claims Settlement Office. If you hire one they are your advocates for you.
Breast Implant Lawyers Accepting Dow Corning Breast Implant ClaimsOur Breat Implant lawyers are reviewing Dow Corning Breast Implant Claims for women implanted with Dow Corning implants prior to June 1, 1993 and who are registered with the SF-DCT.
We are here to help with your Dow Corning silicone breast implant claims and will connect you with a female silicone breast Implant lawyer who has been helping women for 2 decades. Our lawyers have helped women obtain settlements for breast implant diseases such as Lupus, Scleroderma and General Connective Tissue Diseases.
DECEMBER 3, 2015
The District Court issued an Order approving the Consent Order To Establish Guidelines for Distributions From The Class 7 Silicone Material Claimants’ Fund. This means that the Court has authorized approved disease claims in Class 7 to be paid and has approved the parties’ agreed interpretation of “marshaling.” The order will become final once the 30-day time period for appeals has expired and no appeals have been filed. Payments can begin once the Order is final. This means that payments will not begin until sometime in January 2016 or thereafter.
DECEMBER 1, 2015
Copy of the SFDCT letter sent to claimaints with an approved Disease Option 2 claim regarding Increased Severity – Please note the deadline date of June 2, 2019 is incorrect. The correct deadline date is June 3, 2019. To read the response, click here.
SEPTEMBER 15, 2015
Omnibus Response to Objections & Submissions Responding to Consent Order to Establish Guidelines for Distribution From Class 7 Silicone Materials Claimants Fund. To read the response, click here.
JULY 29, 2015
Scheduling Order Regarding Consent Order to Establish Guidelines for Distributions from Class 7 Silicone Material Claimants’ Fund. To read the order, click here.
JULY 17, 2015ATTORNEYS:
Wells Fargo, the paying agent for the SF-DCT, requires law firms to provide an updated w-9 before payment can be issued. You can download a copy of the updated w-9 form here. Please complete and return the w-9 to the SF-DCT.
JUNE 12, 2015
Copy of the Notice to Class 7 Claimants Establishing Guidelines mailed by the SFDCT. To read the notice, click here.
JUNE 2, 2015
Judge Hood as issued an Order Authorizing Distribution of the Notice in reference to the Class 7 Consent Order. To read the order, click here.
MAY 26, 2015
CAC FILES MOTION ASKING FOR APPROVAL TO PAY CLASS 7 CLAIMS AND TO RESOLVE THE DISPUTE CONCERNING PREVIOUSLY DENIED “MARSHALING” CLAIMS
On Friday, May 22, 2015, the CAC filed a proposed Consent Order asking the Court to authorize payment of disease claims for Class 7 claimants. Most claimants in Class 7 have been previously paid a $600 Expedited Release Payment, a Foreign Gel Claimant Payment, or a $3,000 Cash-Out Offer. Claimants that rejected the Cash-Out Offer and elected for a full disease review have been waiting for payment on their approved disease claim. With the filing of the motion, the CAC hopes that these claimants can now be paid once the Consent Order is entered by the Court.
In addition, the CAC has reached an agreement with Dow Corning regarding thousands of Class 7 claims that were previously denied by the SF-DCT on the grounds that the claimant allegedly had not “marshaled” their recoveries from their primary manufacturer (Bristol, Baxter). Under this agreement, claims will be reviewed to determine if the claimant was eligible to apply for disease compensation from the Revised Settlement Program. If so, then that claimant cannot apply for the same disease in Class 7. However, if a claimant was not eligible to receive benefits for a particular disease in the RSP, then that claimant may seek compensation from Class 7.
For example, if a claimant was an Other Registrant in the RSP, the only disease option she was eligible for was Disease Option 2 (called Long Term Benefits). Other Registrants were not eligible for Disease Option 1 (Fixed Benefits) and diseases like ACTD. These claimants may now seek compensation for Disease Option 1 from Class 7.
The SF-DCT will re-review the claims that were previously denied and will send eligible claimants either a $600 Expedited Release Payment or $3,000 Cash-Out Payment. The Cash-Out Payment is available only to those claimants who submitted a disease claim in 2006. Claimants may reject the Cash-Out Payment and instead elect for a full disease review; however, if the claim is not approved, they will not be eligible for the Cash-Out Offer again.
MAY 4, 2015
The MDL Common Benefit Trust fund has announced that it will offer women who were not compensated for Explantation in either the MDL or Dow Corning Settlement a chance to apply for $5,000 explant payment. For more information about this program, please click here. Please note that this program is not affiliated with either the RSP or Dow Corning Settlement Plan.
If you are having difficulty getting your medical insurance to cover the cost of the explant surgery, there is a new resource for women. The Insurance Coverage Assistance Program will be available to provide advice and assistance on how to assess this Medicare, Medicaid, and health care coverage for issues related to breast implants. This program is to be operated by the National Center for Health Research, a consumer-oriented non-profit group in Washington, D.C., that has helped women seek insurance coverage for breast implant removal. The National Center currently operates the breastimplantinfo.org website. You may email them at email@example.com with your name and email address for more information, including their toll-free number. If you do not have access to email, you can call them at 202-223-4000.
FEBRUARY 10, 2015
On January 27, 2015, the Court of Appeals reversed the District Court’s authorization to make 50% partial Premium Payments. Fortunately, the SF-DCT has already made 98% of the partial Premium Payments to eligible, approved claimants. This money does not need to be repaid. Claimants can keep the partial Premium Payment checks that were issued to them. Unfortunately, the remaining 2% of claimants who did not receive their partial Premium Payment check (or returned it for reissuance, or who had lost checks) are on hold pending either a consensual resolution to pay their claims or a court order. A copy of the ruling is under the tab “Court Orders.”
February 10, 2015,
CAC filed a petition for rehearing on this ruling, asking the Court of Appeals to reconsider or rehear the issue based on what the CAC believes are two serious legal errors. A copy of the petition is under the tab “Appeals to the 6th Circuit” and then under the sub-tab “Premium Payments.”
IF YOU NEED HELP WITH YOUR DOW CORNING BREAST IMPLANT CLAIM CONTACT US TODAY
If you have a silicone breast implant that has ruptured or is leaking you may have unusual silicone levels in your blood. Leaking or ruptured silicone breast implants and result in very serious diseases due to silicone poisoning.
We suggest you get your blood levels tested if you have any symptoms of silicone toxicity or just to play it safe.
- Muscle inflammation
- Chemical sensitivity and sensitivities to perfume, smoke and other inhalants
- Joint pain
- Anxiety and depression
- Hair loss
- Memory loss
- Foggy thinking
- Night sweats
- Tingling in the hands and feet
- Abdominal pain
- Chest pain
- Other autoimmune disorders, including rheumatoid arthritis and Sjogren’s syndrome, scleroderma, fibromayalgia, and multiple sclerosis
Dow Corning Breast Implants Silicone Poisoning Alert
Silicone Poisoning Is Serious
Many Women With Dow Corning Breast Implants Have Developed Auto Immune Disorders
DOW Corning Claimant’s Should Get Silicone Medical Testing
There are two medical tests for silicone in the body.
1.) Silicone Antibodies – UNILAB Test #8099 Cpt 86318
Regular 4ml Serum at room temperature = Analytic time 7-10 days
2.) Silicon Levels – UNILAB Test# 9025 CPT84285
Minimum 2ml to 4ml Serum Analytic time 7-10 days
These tests are available through your physician or a laboratory or walk in testing center. You may have to pay cash for these tests. You may have to call your local medical laboratory and ask for the code numbers. The tests were developed by a rheumatologist at the University of California at Los Angeles.
You can try a local testing laboratory. There are testing labs that will do tests without a prescription. You can get the codes from a UNILAB in your area.
News Regarding the Dow Corning Expedited Release Checks
The Settlement Facility Dow Corning Trust has recently decided to send Expedited Release Payments in the amount of $2,000 to all Dow claimants whose cases are idle.
Important Information Regarding Accepting This Offer
Be aware that if you accept this payment you can NEVER apply for a disease claim in the future, even if you become sick.
What Should I Do Id I Receive An Expedited Release Check?
If you receive an expedited release check in the mail, you should not cash it. Call us to speaker to a Dow Corningg Breast Implant lawyer to make sure you are doing the right thing.
Dow Corning Settlement Alert
If you cash the expedited release check you will be agreeing to settle your claim and can never get any additional funds.
Breast Implant Helpline keeps you up to date on all the latest medical breakthoughs
Arimidex Prevents First Breast Cancers
Published: Dec 12, 2013 | Updated: Dec 12, 2013
By Crystal Phend, Senior Staff Writer, MedPage Today
Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania
Anastrozole, an aromatase inhibitor, reduces the incidence of breast cancer in high-risk postmenopausal women.
Side effects associated with estrogen deprivation, were only slightly more frequent in the anastrozole group than in the placebo group.
SAN ANTONIO — Anastrozole (Arimidex) reduced the risk of breast cancer by 53% in high-risk postmenopausal women, a primary prevention trial showed.
The aromatase inhibitor cut the incidence to 2% over 5 years compared with 4% on placebo (P<0.0001), Jack Cuzick, PhD, of Queen Mary University of London, and colleagues found in the IBIS-II trial.
The number needed to treat was 36 to prevent one breast cancer in 7 years of follow-up, the researchers pointed out here at the San Antonio Breast Cancer Symposium and simultaneously online in The Lancet.
That primary prevention effect was larger than reported with tamoxifen or raloxifene (Evista) and similar to what was seen with fellow aromatase inhibitor exemestane (Aromasin) in the MAP.3 trial.
“This finding, along with the fact that most of the side-effects associated with estrogen deprivation were not attributable to treatment, provides support for the use of anastrozole in postmenopausal women at high risk of breast cancer,” Cuzick’s group argued.
The findings likely will put anastrozole in line to be added to breast cancer prevention guidelines, like exemestane was earlier this year, commented Matthew Goetz, MD, a medical oncologist at the Mayo Clinic in Rochester, Minn.
“I think the guidelines will probably be updated to reflect the fact that we now have level 1 evidence that both a steroidal (exemestane) and a nonsteroidal [anastrozole] aromatase inhibitor are effective in the primary prevention setting,” he told MedPage Today, calling the results reassuring.
However, David A. Cameron, MD, MSc, of Scotland’s Edinburgh Cancer Centre, wasn’t so convinced.
The key question is whether any primary prevention drugs actually prevent breast cancer deaths and improve overall survival for the price in toxicity, which no trial has yet shown, he argued in a commentary accompanying the Lancet paper.
Instead of true prevention of clinically significant, life-threatening breast cancers, “the consistent finding of an increased effect of prevention therapy on hormone-receptor-positive tumors supports the prediction made by modelling data that pharmacological prevention of breast cancer is actually early treatment of extant subclinical tumors,” he wrote.
“With two-thirds of the anastrozole benefit in screen-detected cancers, in view of their better outcomes, the likelihood of an eventual breast cancer mortality benefit seems small.”
Goetz disagreed, though, pointing to the fact that anastrozole halved the risk of invasive cancers in the trial (rate 2% versus 3%, HR 0.50, 95% confidence interval 0.32-76).
The impact was driven by a 58% reduction in risk of invasive estrogen receptor (ER)-positive cancer, whereas no significant benefit accrued for invasive ER-negative tumors.
“It’s premature to say the trial is not a success,” he told MedPage Today. “This drug is reducing incidence of ER-positive breast cancer and for those often times the mortality effect is not seen for many years. Often recurrence is occurring in the second decade after being diagnosed.”
The International Breast cancer Intervention Study II (IBIS-II) included 3,864 postmenopausal women at high risk of breast cancer, defined by family history or prior diagnosis of ductal carcinoma in situ, lobular carcinoma in situ, or atypical ductal hyperplasia.
They were randomized to take 1 mg anastrozole or placebo daily for 5 years.
The trial had a pragmatic design, with imaging and other follow-up at the end of the 5 years based on local practice without central review. Women had a mammogram and breast exam at baseline (unless recently done) and every 2 years thereafter during the study.
At the median 5 years of follow-up, 40 anastrozole-treated women compared with 85 on placebo had developed any breast cancer, for a hazard ratio of 0.47 (95% CI 0.32-0.68).
The cumulative incidence was predicted to rise to 2.8% and 5.6%, respectively, after 7 years.
The advantage of the aromatase inhibitor also was greater in preventing high-grade cancers, with no impact on intermediate- or low-grade tumors.
“Although highly significant, this finding could have been a result of chance, because other indicators of aggressive or fast growing tumours (eg, node positivity and large tumour size) were not differentially affected,” the researchers warned.
Overall mortality was similar between groups (18 deaths with anastrozole versus 17 with placebo).
No specific causes of death were more common in one group than the other (P=0.836), but there were fewer cancers outside the breast, which the researchers called “surprising, especially for colorectal cancers, in which hormone replacement therapy is known to be protective and for which the ATAC trial suggested a non-significant increase with anastrozole compared with tamoxifen in the adjuvant setting.”
Despite guideline support, uptake of primary prevention has been low among eligible women. And that’s not likely to change with more of the same kind of efficacy data, Goetz suggested.
Side effects and cost are more likely to be deciding factors in the absence of any evidence that it will save women’s lives, Cameron explained.
He was critical of the toxicity profile, noting that about half or more of the women in both groups in the trial had musculoskeletal and vasomotor symptoms, while about a fifth had gynecologic adverse events.
“Although the increase in frequency with anastrozole [versus placebo] was modest for musculoskeletal (6%) and vasomotor (8%) events, more than 100 to 200 additional women had these symptoms in the anastrozole group compared with the placebo group — quite often to a moderate or severe level — to prevent 15 symptomatically diagnosed breast cancers,” Cameron argued.
The researchers took a different view of the same finding.
“Although many side-effects recorded have been associated with estrogen deprivation, they were only slightly more frequent in the anastrozole group than in the placebo group, indicating that most of these symptoms are not drug related,” they wrote, suggesting that disseminating that fact could help curb dropouts.
The study was funded by Cancer Research UK, the National Health and Medical Research Council Australia, Sanofi-Aventis, and AstraZeneca.
Cuzick reported having received funding for IBIS-II from Sanofi-Aventis and AstraZeneca, and being a paid member of a speaker’s bureau for AstraZeneca.
Cameron and Goetz reported having no conflicts of interest to disclose.
Right now bellwether trials are underway for vaginal mesh lawsuits. Thousands of women have suffered from these vaginal mesh devices. Our new vaginal mesh department has a vaginal mesh lawsuit lawyer for you.
VAGINAL MESH AND RELATED BLADDER MESH PRODUCTS ARE THE BIGGEST PANDEMIC EFFECTING WOMEN Over 300,000 women are effected and so many have their own stories of pain and suffering,
Manufacturers of Mesh Products Include:
Johnson & Johnson,
Prolene Polypropylene Mesh Patch,
Avaulta Plus BioSynthetic Support System,
Avaulta Solo Synthetic Support System,
Pelvitex Polypropylene Mesh,
American Medical Systems or AMS,
Advantage Sling System,
Obtryx Curved Single,
Obtryx Mesh Sling,
Prefyx Mid U Mesh Sling System,
Prefyx PPS System,
The vaginal mesh Continues to effect women and alter the lives of 1000’s of women and their families.
If you or a loved one has a failed vaginal mesh and is ready
to stand up for justice call now to file a vaginal mesh lawsuit
Breast Implant Helpline keeps you updated on all breast implant news. Years after the Dow Corning Silicone Breast Implant disaster a new silicone breast implant hits the market. The FDA has approved a new silicone gel breast implant from Johnson & Johnson.
Next Generation breast Implant?
The Food and Drug Administration said it has approved a next-generation silicone breast implant from Mentor, a unit of New Brunswick-based Johnson & Johnson. Ladies let’s remember who this is. The same folks that bring you the vaginal mesh implant that is ruing lives nationwide. We watch with skepticism. The company’s MemoryShape breast implant uses a cross-linking gel design that the FDA says is firmer than previous implants. FDA regulators approved the new implant for breast enhancement and reconstruction in women at least 22 years old.
Can Silicone Breast Implants Make A Comeback?
Silicone gel implants have made a comeback recently after safety concerns kept them off the market for nearly 25 years.
The FDA banned sales of silicone breast implants in 1992, saying manufacturers had not provided enough medical data showing their safety and effectiveness. At the time, there were worries about a connection to a variety of diseases, including cancer and lupus. Alarming cases of ruptures added to the concern. Women are still waiting on settlements from the Dow Corning Class Actions and a new breast implant explant program has been announced.
The FDA said Friday it approved Mentor’s new implant based on studies tracking six years of data in 955 women. The agency said complications with Mentor’s MemoryShape implants were similar to those from previously approved silicone gel implants.
FDA is requiring Mentor to meet a number of requirements in connection with the new approval, including:
• Tracking the 955 women with the new implant
• Conducting a new study of 2,500 women who receive the new implant
• Evaluating women’s comprehension and perception of the implant’s labeling
• Analyzing any implants that are removed from women and returned to the manufacturer
More than one in five women who get implants for breast enhancement will need to have them replaced within five years, accord to an FDA analysis of company data released in 2011. Despite that relatively high failure rate, FDA regulators concluded that the silicone-gel implants are basically safe, as long as women understand they come with complications. Some critics of the implants say the failure rate may be even higher, since many women have dropped out of the company studies.
We will be watching.
You may have received a letter from the Dow Corning Trust explaining a Breast Implant explant program. For help in understanding your rights and to speak to a breast implant explant lawyer contact the Breast Implant Helpline today
There is a Breast Implant Explant Program Deadline
The final deadline to submit an Explant Claim to the SF-DCT is June 2, 2014. You must have acceptable Proof of Manufacturer before you can be considered for the Explant benefit. The Explant benefit is $5,000.00. To qualify for this benefit, you must have your Dow Corning implants removed and not replaced with silicone.
It can take six months or longer to schedule an explant surgery and to obtain the necessary medical records from your surgeon or hospital. If you are eligible to apply for this benefit, you should keep this deadline date in mind. Do not wait to discuss your explant surgery with your doctor. This should be done as soon as possible.
What Is Breast Implant Explant Surgery?
Breast explant surgery is mplant removal. Explant surgery is the process by which your breast implants are removed from the breasts. Depending upon the reason for the surgery, additional material may be removed.
Dow Corning Explant Benefits Notice
EXPLANT DEADLINE IS JUNE 2, 2014
The Settlement Facility will mail letters to Class 5 and 6 claimants on April 26, 2013 reminding them of the Explant Deadline of June 2, 2014.
What is the Explant Deadline? To be eligible for the $5,000 Explant benefit (Class 5 only), you must have your Dow Corning breast implant removed by June 2, 2014 and you cannot receive another silicone gel breast implant after that. To file a claim, you must submit the Explant Form and the operative statement from the Explant surgery. Only claimants in Class 5 and 6.1 (non-U.S. Dow Corning breast implant claimants) are eligible for the Explant Payment.
June 2, 2014 may seem like a long time away, but our experience has been that it often takes up to 6 months or more to schedule an appointment with your surgeon, schedule the surgery, and obtain the necessary medical reports (such as the Operative Report) to submit a claim by the deadline.
If your Dow Corning breast implant is not removed by June 2, 2014, then you cannot apply for the Explant benefit.There is still money available to help you remove your defective Dow implants. There is money available to help you remove your defective breast implants
Call the Dow Corning breast Implant Helpline and we will locate a nationwide breast implant lawyer for you. Dow Corning breast Implant Claim Helpline is sponsoring a Nationwide Program to help women currently registered with Dow corning trust to get what they deserve for the damage and injury of their Dow corning silicone Breast Implants. You must be registered with the Dow corning trust settlement office to participate in this free Breast Implant lawyer assistance program. This Free breast implant claims helpline program is for woman who:
- are currently listed with the Dow settlement Trust
- Silicone Breast Implant Dow Corning Claim current registrant
- Are currently under the MDL-926 program
- Have received a rejection notice from their current Dow Breast implant Claim Lawyer
- Are seeking a new Dow corning Breast Implant attorney
Silicone Gel Breast Implants Class Action
April 2012 Updates – Dow Settlement
The SF-DCT has moved, and their new address effective April 3, 2012 is:
3200 SW Freeway, Ste. 1500
Houston, TX 77027
Their telephone number remains the same: 1-866-874-6099.
Their P.O. Box also remains the same: P.O. Box 52429, Houston, TX 77052
Regarding Premium Payments: the matter of if and when the SF-DCT issues premium payments is now under consideration by the Court. We do not know when the Court will issue a ruling. As soon as an order is entered, we will post it on our website and contact any potentially eligible LCHB clients.
Regarding Class 7 Payments: Because some unreviewed Class 7 claims were found during an audit at the SF-DCT, the SF-DCT cannot issue any Class 7 payments until those unreviewed claims are processed and given the one year time period within which to cure deficiencies. As of this date, the SF-DCT cannot predict the exact date when Class 7 payments are going to be made, but it will probably be at least another year before they can issue payments.
REMINDER ABOUT THE EXPLANT DEADLINE: The final deadline to submit an Explant Claim to the SF-DCT is June 2, 2014. Please remember that you must have acceptable Proof of Manufacturer before you can be considered for the Explant benefit. The Explant benefit is $5,000.00 (five thousand dollars), and in order to qualify for this benefit, you must have your Dow Corning implants removed and not replaced with silicone.
Please keep in mind that it can sometimes take six months or longer to schedule an explant surgery and to obtain the necessary medical records from your surgeon or hospital. Therefore, if you want to apply for this benefit, you should keep this deadline date in mind, and not wait too long to discuss your potential explant surgery with your doctor.
A Nationwide free Service Sponsered by the Breast Implant Helpline
for women with Dow corning claims in: Auburn AL; Birmingham AL; Dothan AL; Gadsden AL; Huntsville AL; Mobile AL; Montgomery AL; Muscle Shoals AL; Tuscaloosa AL; Anchorage AK; Fairbanks AK; Juneau AK; Flagstaff AZ; Sedona AZ; Mohave County AZ; Phoenix AZ; Prescott AZ; Show Low AZ; Sierra Vista AZ; Tucson AZ; Yuma AZ; Fayetteville AR; Fort Smith AR; Jonesboro AR; Little Rock AR; Bakersfield CA; Chico CA; Fresno CA; Humboldt County CA; Inland Empire CA; Long Beach CA; Los Angeles CA; Mendocino (new) CA; Merced CA; Modesto CA; Monterey CA; O.C. CA; Oakland CA; Palm Springs CA; Palmdale CA; Redding CA; Sacramento CA; San Diego CA; San Fernando Valley CA; San Francisco CA; San Gabriel Valley CA; San Jose CA; San Luis Obispo CA; San Mateo CA; Santa Barbara CA; Santa Cruz CA; Santa Maria CA; Siskiyou CA; Stockton CA; Susanville CA; Ventura CA; Visalia CA; Boulder CO; CO Springs CO; Denver CO; Fort Collins CO; Pueblo CO; Rockies CO; Western Slope CO; Eastern CT CT; Hartford CT; New Haven CT; Northwest CT CT; Wilmington DE; Dover DE; Newark DE; Pike Creek DE; Bear DE; Washington D.C. District of Columbia; Daytona FL; Fort Myers FL; Ft Lauderdale FL; Gainesville FL; Jacksonville FL; Keys FL; Lakeland FL; Miami FL; Ocala FL; Orlando FL; Panama City FL; Pensacola FL; Sarasota FL; Space Coast FL; St. Augustine FL; Tallahassee FL; Tampa FL; Treasure Coast FL; West Palm Beach FL; Albany GA; Athens GA; Atlanta GA; Augusta GA; Brunswick GA; Columbus GA; Macon GA; Northwest GA GA; Savannah GA; Statesboro GA; Valdosta GA; Big Island HI; Honolulu HI; Kauai HI; Maui HI; Boise ID; East ID ID; Lewiston ID; Twin Falls ID; Bloomington IL; Carbondale IL; Chambana IL; Chicago IL; Decatur IL; La Salle County IL; Mattoon IL; Peoria IL; Rockford IL; Springfield IL; Western IL IL; Bloomington IN; Evansville IN; Ft Wayne IN; INpolis IN; Kokomo IN; Lafayette IN; Muncie IN; Richmond IN; South Bend IN; Terre Haute IN; Cedar Rapids IA; Des Moines IA; Dubuque IA; Fort Dodge IA; IA City IA; Mason City IA; Ottumwa IA; Quad Cities IA; Sioux City IA; Waterloo IA; Lawrence KS; Manhattan KS; Topeka KS; Wichita KS; Bowling Green KY; Eastern KY KY; Lexington KY; Louisville KY; Owensboro KY; Western KY KY; Baton Rouge LA; Lafayette LA; Lake Charles LA; Monroe LA; New Orleans LA; Shreveport LA; Portland ME; Lewiston ME; Bangor ME; West Scarborough ME; Annapolis MD; Baltimore MD; Cumberland Valley MD; Eastern Shore MD; Frederick MD; Western MD MD; Boston Massachusetts; Cape Cod Massachusetts; South Coast Massachusetts; Springfield Massachusetts; Worcester Massachusetts; Ann Arbor MI; Battle Creek MI; Central MI MI; Detroit MI; Flint MI; Grand Rapids MI; Holland MI; Jackson MI; Kalamazoo MI; Lansing MI; Monroe MI; Muskegon MI; Northern MI MI; Port Huron MI; Saginaw MI; Southwest MI MI; Upper Peninsula MI; Duluth MN; Mankato MN; Minneapolis MN; St Paul MN; Rochester MN; St. Cloud MN; Biloxi MS; Hattiesburg MS; Jackson MS; Meridian MS; Natchez MS; North MS MS; Columbia/Jeff City MO; Joplin MO; Kansas City MO; Kirksville MO; Lake of the Ozarks MO; Southeast MO MO; Springfield MO; St. Joseph MO; St. Louis MO; Billings MT; Missoula MT; Great Falls MT; Bozeman MT; Butte MT; Grand Island NE; Lincoln NE; North Platte NE; Omaha NE; Scottsbluff NE; Las Vegas NV; Reno NV; Manchester NH; Nashua NH; East Concord NH; Concord NH; Derry Village NH; Central Jersey NJ; Jersey Shore NJ; North Jersey NJ; South Jersey NJ; Albuquerque New Mexico; Santa Fe New Mexico; Albany NY; Binghamton NY; Buffalo NY; Catskills NY; Chautauqua NY; Elmira NY; Finger Lakes NY; Glens Falls NY; Hudson Valley NY; Ithaca NY; Long Island NY; New York City NY,Brooklyn,Queens,Staten island,Bronx,White Plains,New Rochelle; Oneonta NY; Plattsburgh NY; Potsdam NY; Rochester NY; Syracuse NY; Twin Tiers NY; Utica NY; Watertown NY; Westchester NY; Asheville NC; Boone NC; Charlotte NC; Eastern NC; Fayetteville NC; Greensboro NC; Hickory NC; Outer Banks NC; Raleigh NC; Wilmington NC; Winston Salem NC; Fargo ND; Akron OH; Canton OH; Ashtabula OH; Athens OH; Chillicothe OH; Cincinnati OH; Cleveland OH; Columbus OH; Dayton OH; Huntington/Ashland OH; Lima/Findlay OH; Mansfield OH; Sandusky OH; Toledo OH; Tuscarawas County OH; Youngstown OH; Zanesville/Cambridge OH; Lawton OK; OK City OK; Stillwater OK; Tulsa OK; Bend OR; Corvallis OR; East OR OR; Eugene OR; Medford OR; OR Coast OR; Portland OR; Roseburg OR; Salem OR; Allentown PA; Altoona PA; Cumberland Valley PA; Erie PA; Harrisburg PA; Lancaster PA; Meadville PA; Philadelphia PA; Pittsburgh PA; Poconos PA; Reading PA; Scranton PA; State College PA; Williamsport PA; York PA; Providence RI; Warwick RI; Cranston RI; Pawtucket RI; East Providence RI; Woonsocket RI; Charleston SC; Columbia SC; Florence SC; Greenville SC; Hilton Head SC; Myrtle Beach SC; Sioux Falls SD; Rapid City SD; Aberdeen SD; Chattanooga TN; Knoxville TN; Memphis TN; Nashville TN; Tri-cities TN; Abilene TX; Amarillo TX; Austin TX; Beaumont TX; Brownsville TX; College Station TX; Corpus Christi TX; Dallas TX; Denton TX; El Paso TX; Fort Worth TX; Galveston TX; Houston TX; Huntsville TX; Killeen TX; Laredo TX; Lubbock TX; Mcallen TX; Odessa TX; San Antonio TX; San Marcos TX; Texarkana TX; Texoma TX; Tyler TX; Victoria TX; Waco TX; Wichita Falls TX; Logan UT; Ogden UT; Provo UT; Salt Lake City UT; St. George UT; Burlington VT; Essex Junction VT; Bennington VT; Charlottesville VA; Chesapeake VA; Danville VA; Fredericksburg VA; Hampton VA; Harrisonburg VA; Lynchburg VA; New River Valley VA; Newport News VA; Norfolk VA; Portsmouth VA; Richmond VA; Roanoke VA; SouthWV VA; Suffolk VA; VA Beach VA; Bellingham WA; Everett WA; Moses Lake WA; Olympia WA; Pullman WA; Seattle WA; Spokane WA; Tacoma WA; Tri-cities WA; Wenatchee WA; Yakima WA; Charleston WV; Huntington WV; Martinsburg WV; Morgantown WV; Parkersburg WV; Southern WV WV; Wheeling WV; Appleton WI; Eau Claire WI; Green Bay WI; Janesville WI; La Crosse WI; Madison WI; Milwaukee WI; Racine WI; Sheboygan WI; Wausau WI; Cheyenne WY; Casper WY; Laramie WY; Gillette WY;
Dow Corning Breast Implant Helpline and Our Dow Corning Breast Implant Lawyers are helping Dow Corning Claimants.
Below you will Find the most recent updates from the Claimants advisory official committee
official committee appointed by the U.S. District Court in the Eastern District of Michigian to represent the interests of claimants in the Dow Corning Bankruptcy Settlement Plan. This website has information concerning the Settlement Facility for the Dow Corning Trust (SF-DCT). We welcome all comments and questions so that we can make this website informative and useful. Contact us by phone at 419-394-0717, by fax at 419-394-1748, by email at or by U.S. mail at: Claimants' Advisory Committee, P.O. Box 665, St. Marys, OH 45885.
MARCH 30, 2012
The Settlement Facility offices are moving to a new location in Houston, Texas on March 30th, 2012. During the move, the phones, emails and access to the "My Claim" feature on the SF-DCT website will be shut down from March 27th to April 2nd, 2012. This means representatives will not be able to answer any calls or emails during this time. Please be patient during this transition.
The mailing address for claims forms will remain the same:
P.O. Box 52429, Houston, Texas 77052-2429
To send documents to the Settlement Facility by overnight mail (Federal Express or a similar service), the new address effective April 3, 2012 is:
3200 SW Freeway, Suite 1500
Houston, TX 77027
The phone number for the Settlement Facility will remain the same: 866-874-6099.
JANUARY 14, 2012
UPDATE ON PREMIUM PAYMENT MOTION
The court heard oral argument from the parties on the Finance Committee's motion requesting authority to make Premium Payments. As we anticipated in previous newsletters, the court did not rule on the motion at the hearing. The matter is now under consideration by the court. We do not know when the court will issue a ruling. As soon as an order is entered, we will send out a newsletter and update our website with the information.
The briefs are on the CAC website (www.tortcomm.org) under the heading "Pending Motions." If you are not receiving the Enewsletters via Email and you have registered your email address, please check your spam filters to make sure the emails are not being filtered out.
JANUARY 5, 2012
The briefing on the Finance Committee's motion requesting approval of Premium Payments to approved Rupture and Disease claimants is now complete. Copies of the briefs are available on the CAC's website. The hearing on this matter will be on January 31st. For more information, please read the January 5, 2012 e-newsletter available on this site.